South Texas Alzheimer’s Disease Center Biomarker Core

生物标志物允许更深入地了解生物学，改善风险预测，诊断和鉴定， 阿尔茨海默病和相关病症（ADRD）的临床前和临床阶段。的总体目标 生物标志物核心（BC）有两个方面：（1）为STAC提供生前生物库服务，即 收集和储存临床核心中登记的所有人员（患者、护理伙伴和 对照组），在初次和年度随访访视时估计为265/年， 未入组CC但由另一个STAC核心（如人群核心研究）转介的人员的生物标本 入组者、临床试验患者、脑库捐献者），并与数据、统计管理和 管理核心目录，跟踪和共享这些样本。(2)为了鉴定用于检测的生物标志物， 临床前ADRD，用于预测进展为MCI和ADRD痴呆的风险，并用于鉴别诊断 以及识别ADRD MCI和痴呆的亚型。BC由AD的领导者Xianlin Han博士领导 代谢组学/脂肪组学和Mini Jacob，MD，PhD，研究ADRD中的感觉运动生物标志物。我们有 高级老年病学家、GRECC和Pepper临床中心主任、医学博士萨拉·埃斯皮诺萨补充说 核心为了实现这些目标：首先，我们将收集，处理，存储，共享和跟踪生物标本 （血清、血浆、外周血单核细胞、DNA、RNA、CSF和唾液或粪便（如有指征）），以及 来自个人的非侵入性感觉运动测量并与其临床、成像、基因组和 神经病理学数据。我们将使用最新的生物化学和分子方法，并应用最佳实践 程序.其次，我们将通过以下方式验证或鉴定西班牙裔人群中的生物标志物： 与CC、PNC、GMC、IC和NPC合作，将标志物与临床诊断、病程、肿瘤大小 疾病、成像和神经病理学。我们将通过提交样本和 管理数据到NACC、NCRAD和NIAGADS等存储库。第三，我们将确定新的CSF， 疑似非阿尔茨海默病病理生理学（SNAP）患者的血浆代谢生物标志物 伴或不伴2型糖尿病（T2 DM）。我们将与CC、PNC和IC合作， SNAP伴和不伴T2 DM的个体（总计300-400例，一半T2 DM，约80例/年）， 区分典型生物标志物定义的AD（A+/T+/N+）和SNAP的代谢生物标志物 有和没有T2 DM。我们希望在SNAP中找到一个独特的生物标志物和代谢特征， 这将有助于我们更好地了解SNAP的生物学，并可能有助于 诊断和治疗。总之，BC将收集和共享生物标本，并生成和共享 西班牙裔美国人的广泛生物标志物数据，以建立一个独特的资源，了解异质性， ADRD在南德克萨斯州和开发AD个性化治疗。

Biomarkers permit a deeper understanding of biology, improve risk prediction, diagnosis and prognostication at pre-clinical and clinical stages of Alzheimer Disease and Related Disorders (ADRD). The overall goals of the Biomarker core (BC) are two-fold: (1) To provide ante-mortem biobanking services for STAC, that is to collect and store biospecimens for all persons enrolled in the Clinical Core (patients, care partners and controls), an estimated 265/year at their initial and annual follow-up visits, and similarly collect and store biospecimens for persons not enrolled in the CC but referred by another STAC core (e.g. population core study enrollees, clinical trial patients, brain bank donors) and working with the Data, Statistical Management and Administrative Cores catalog, track and share these samples. (2) To identify biomarkers for detecting preclinical ADRD, for risk prediction of progression to MCI and ADRD dementia, and for differential diagnosis and identifying subtypes of ADRD MCI and dementia. The BC is led by Xianlin Han, PhD, a leader in AD metabolomics/lipomics and Mini Jacob, MD, PhD, studying sensory-motor biomarkers in ADRD. We have added Co-I Sara Espinoza, MD, a senior geriatrician who is Director of the GRECC and Pepper Center Clinical Core. To achieve these goals: Firstly, we will collect, process, store, share and track biospecimens (serum, plasma, peripheral blood monocytes, DNA, RNA, CSF and saliva or stool when indicated), as well as non-invasive sensorimotor measures from individuals and link to their clinical, imaging, genomic and neuropathologic data. We will use the latest biochemical and molecular methods and apply best practice procedures. Secondly, we will validate or identify biomarkers among the Hispanic population by collaborating with the CC, PNC, GMC, IC and NPC to correlate the markers with clinical diagnoses, course of disease, imaging and neuropathology. We will make these data publicly available by submitting samples and curated data to repositories such as NACC, NCRAD and NIAGADS. Thirdly, we will identify novel CSF and plasma metabolic biomarkers in individuals with Suspected Non-Alzheimer Pathophysiology (SNAP) with or without type 2 diabetes mellitus (T2DM). In collaboration with the CC, PNC and IC we will identify individuals with SNAP with and without T2DM (300-400 in total, half T2DM at rate of ~80/year), identify plasma metabolic biomarkers distinguishing between classical biomarker-defined AD (A+/T+/N+) and SNAP in persons with and without T2DM. We expect to find a unique biomarker and metabolic signature in SNAP compared to AD and in SNAP with T2DM that will help us better understand the biology of SNAP and may help with diagnosis and treatment. In summary, BC will collect and share biospecimens, and generate and share extensive biomarker data in Hispanics to establish a unique resource for understanding the heterogeneity of ADRD in South Texas and for development of AD personalized treatments.